Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TDM-105795 Safety and PK in Men with Androgenetic Alopecia
NCT05244980Phase 1Completed
- Sponsor
- TechnoDerma Medicines Inc.
- Start
- Feb 2022
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in androgenetic alopecia (AGA) comparing TDM-105795 with Placebo (2 arms). Primary endpoints: Incidence rate of any local and systemic Adverse Events (AEs) at 42 days, Number of subjects with presence (and severity) of local skin reactions (LSRs) at 42 days and 4 more. Started Feb 2022; status: completed.
02
Drugs
TDM-105795
03
Conditions
androgenetic alopecia (AGA)
Beyond the preview
Go deeper on NCT05244980.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05244980.